Join the club for FREE to access the whole archive and other member benefits.

Stem cell biotech MoglinBio secures seed investment


Key points from article :

MoglingBio, a privately held biotech company, completes its first seed investment.

Sole investor is venture capital firm Kizoo Technology Capital.

Company is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic system.

Normalizing CDC42 activity can restore structure, order and functionality in those aged stem cells. 

Underlying technology was developed over 15 years by its scientific co-founders, Prof. Yi Zheng and Prof. Dr. Hartmut Geiger.

“... will allow us to pursue our goal of rejuvenating aging stem cells, " said Dr. Jürgen Reess, CEO.

“We believe that MoglingBio’s technology is groundbreaking by truly rejuvenating old stem cells" – Frank Schueler, Kizoo's MD.

Kizoo is focused on rejuvenation biotech so it must see potential in normalizing CDC42 activity

Mentioned in this article:

Click on resource name for more details.

Frank Schueler

Managing Director of Kizoo Technology Capital

Juergen Reess

Co-founder and CEO at Mogling Bio, Managing Director at Cellerys AG

KIZOO Technology Ventures

Company providing financing and its focus is on rejuvenation biotech

Mogling Bio

Biopharmaceutical company developing new treatments for rejuvenating old stem cells

Yi Zheng

Director of Experimental Hematology and Cancer Biology, Co-Director at Cancer and Blood Diseases Institute